A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) (NCT06637423)
A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)
🩺 Plain-English Summary (8th-Grade Level)
The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future studies to learn how well the drug works.
Who can join: Review the eligibility criteria below.
Location: Michael G Oefelein Clinical Trials ( Site 0053) — Bakersfield, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- Michael G Oefelein Clinical Trials ( Site 0053) — Bakersfield, California
- Moffitt Cancer Center ( Site 0057) — Tampa, Florida
- Northwestern University ( Site 0051) — Chicago, Illinois
- Johns Hopkins University ( Site 0055) — Baltimore, Maryland
- Princess Margaret Cancer Centre ( Site 0003) — Toronto, Ontario
- CIUSSS de l'Estrie-CHUS ( Site 0002) — Sherbrooke, Quebec
- Hôpital Claude Huriez ( Site 0012) — Lille, Nord
- HENRI MONDOR HOSPITAL ( Site 0011) — Créteil, Val-de-Marne
- Gustave Roussy ( Site 0013) — Villejuif, Val-de-Marne
- Erasmus Medisch Centrum ( Site 0032) — Rotterdam, South Holland
- Hospital Universitario Virgen de la Victoria ( Site 0043) — Málaga, Andalusia
- Hospital Universitario 12 de Octubre ( Site 0042) — Madrid,
- St Bartholomew s Hospital ( Site 0061) — London, London, City of
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-Muscle Invasive Bladder Cancer
- A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer — Birmingham, Alabama
- Study of CG0070 After Transurethral Resection in Patients With IR NMIBC — Tampa, Florida
- A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer — Tucson, Arizona
- Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention — Dallas, Texas
- A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer — Tampa, Florida
- Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment — Basking Ridge, New Jersey
Explore by condition: All Non-Muscle Invasive Bladder Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.